← boardnext 2026-12-30
SLS
Sellas Life Sciences Groupdistress 4/10 · elevated risk$12.080%today-22% from 52w high
Oncology 1
Lead: acute myeloid leukemia · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$107M
Runway
3.8 yrs
Shares 1y
+77%
Price & events
+167.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+2.8%
1W
+33.2%
1M
+160.3%
3M
+183.6%
6M
+556.5%
1Y
+923.7%
2Y
+37.6%
5Y
+115.3%
All
Overview
- Market Cap
- $2.25B
- Volume
- 682.02K
- 52 Week Range
- $1.39 – $15.45
- Total Shares
- 186.03M
- Float Shares
- 185.28M
- Short %
- 32.33%
- % Held by Insiders
- 0.95%
- % Held by Institutions
- 27.82%
- RVOL
- 0.07x
- Beta
- 2.42
Pipeline stages · 2 programs
SLS009, venetoclax, azacitidine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Galinpepimut-S, Azacitidine, Venetoclax, Decitabine, Cytarabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-30 Estimated 50% readout ~2027-02-13 | Phase 1/2 | SLS009, venetoclax, azacitidine | Hematologic Malignancies | — | recruiting |
| 2025-12 | Phase 3 | Galinpepimut-S, Azacitidine, Venetoclax, Decitabine, Cytarabine | Acute Myeloid Leukemia | 127 | active not recruiting |
Catalyst news & presentations · 4
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- this yearreadoutPhase 3galinpepimut-S · Final analysis at 80 eventsSEC 8-K
- October 29, 2025conferencedata presentationsecondaryVirtual R&D Day featuring KOLs discussing AML treatment landscape.SEC 8-K
- January 2025readoutPhase 3GPS · Interim analysis of Phase 3 REGAL trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $28 (+128% upside) · 2 analysts
- 2026-03-12Maxim GroupBuy
- 2025-07-16Maxim GroupBuy
Competitors — acute myeloid leukemia
- ABBVAbbVie Inc.$451.1B · D2
- SNDXSyndax Pharmaceuticals Inc$1.9B · D5
- KURAKura Oncology, Inc.$917M · D5
- FHTXFoghorn Therapeutics Inc.$303M · D4
- DTILPRECISION BIOSCIENCES INC$185M · D6
- BMEABiomea Fusion, Inc.$90M · D6
- INABIN8BIO, INC.$12M · D7
- MBRXMoleculin Biotech, Inc.$11M · D8
- APVOAptevo Therapeutics Inc.$6M · D7
- BPTHBIO-PATH HOLDINGS, INC.$2M · D9
Recent news
- 2026-07-23SLS: SELLAS Life Sciences Group Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
- 2026-07-22SLS Stock Whipsaws As Meme Momentum Meets Biotech Reality - StocksToTrade
- 2026-07-22SELLAS Life Sciences Group Inc (SLS) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
- 2026-07-18Will Near-Complete REGAL Phase 3 GPS Data and New Executive Terms Change SELLAS Life Sciences Group's (SLS) Narrative - Yahoo Finance
- 2026-07-18SELLAS Life Sciences Group (NASDAQ:SLS) surge draws attention to $319 million market-cap deficit ahead of REGAL trial results - TechStock²
- 2026-07-18SELLAS Life Sciences Group (SLS) Stock Looks Rich On Book Value Yet Strong On Returns - Yahoo Finance
- 2026-07-18SELLAS Life Sciences Group (SLS) Stock Pricey Following Phase 3 Trial Buzz - Yahoo Finance
- 2026-07-18SLS News | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.